Dr Reddys launches generic version of Cuprimine Capsules in US
Penicillamine USP is a chelating agent used in the treatment of Wilson's disease.
Hyderabad and Princeton: Hyderabad-based drugmaker Dr Reddy's Laboratories Ltd. has recently announced that the company has launched Penicillamine Capsules USP, 250 mg.
The product is a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).
Dr Reddy's Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.
Penicillamine USP is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy.
Cuprimine is a trademark of Bausch Health Companies Inc.
The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
Dr Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd